Prospective analysis reveals that pretreatment KRAS-mutant ctDNA predicts recurrence risk in colorectal liver metastases, suggesting better monitoring strategies.
Pretreatment KRAS-mutant ctDNA predicts higher recurrence risk and shows an association with lung-predominant metastasis in patients with CRLM after RFA. Integrating ctDNA and KRAS profiling enhances risk stratification and supports personalized surveillance strategies.
No takes yet. Share an insight, caveat, or question.
Lin et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: